Robeco Institutional Asset Management B.V. Buys 126,667 Shares of Humana Inc. $HUM

Key Points

• Robeco Institutional Asset Management B.V. significantly increased its stake in Humana Inc. by 260.9%, acquiring an additional 126,667 shares to own approximately 0.15% of the company worth $42.8 million.
• Humana announced a quarterly dividend of $0.885 per share, representing a 1.2% dividend yield and a payout ratio of 27.17%.
• For its most recent quarter, Humana reported earnings of $6.27 EPS, missing estimates, despite revenue growth of 9.6% year-over-year, totaling $32.39 billion.

Robeco Institutional Asset Management B.V. raised its stake in Humana Inc. (NYSE:HUM - Free Report) by 260.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 175,208 shares of the insurance provider's stock after purchasing an additional 126,667 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.15% of Humana worth $42,835,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Janney Montgomery Scott LLC acquired a new position in Humana during the first quarter worth $1,309,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Humana by 16.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider's stock worth $300,728,000 after purchasing an additional 158,528 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of Humana by 104.2% in the 1st quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider's stock valued at $1,701,000 after purchasing an additional 3,281 shares during the period. Envestnet Asset Management Inc. lifted its stake in Humana by 2.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock valued at $33,256,000 after purchasing an additional 2,950 shares during the last quarter. Finally, Circle Wealth Management LLC bought a new position in Humana during the first quarter worth about $425,000. Institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Shares of NYSE HUM opened at $284.00 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The firm has a market cap of $34.16 billion, a price-to-earnings ratio of 21.80, a P/E/G ratio of 1.51 and a beta of 0.42. The stock's fifty day moving average price is $274.76 and its two-hundred day moving average price is $257.42. Humana Inc. has a one year low of $206.87 and a one year high of $315.35.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the previous year, the firm posted $6.96 EPS. The company's revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.2%. Humana's dividend payout ratio (DPR) is currently 27.17%.

Analyst Ratings Changes

Several analysts have issued reports on HUM shares. Bank of America upped their price objective on Humana from $285.00 to $312.00 and gave the company a "neutral" rating in a research note on Tuesday, September 2nd. Barclays decreased their target price on Humana from $315.00 to $245.00 and set an "equal weight" rating on the stock in a report on Friday. Wells Fargo & Company cut their price target on Humana from $348.00 to $344.00 and set an "overweight" rating for the company in a report on Thursday, August 14th. Mizuho set a $300.00 price objective on shares of Humana in a report on Friday. Finally, Evercore ISI assumed coverage on shares of Humana in a research report on Monday, September 22nd. They issued an "in-line" rating and a $295.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $291.21.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.